BridgeBio (BBIO) director sells 61,031 shares at $63.72 avg

BridgeBio Pharma (BBIO) disclosed an insider transaction by a director on 11/06/2025.

Rhea-AI Filing Summary

BridgeBio Pharma (BBIO) disclosed an insider transaction by a director on 11/06/2025. The director exercised 61,031 stock options at $34.65 per share (code M), receiving shares that same day, and then sold 61,031 shares at a $63.7217 weighted average, within a $63.70–$63.88 range.

Following these trades, the director beneficially owned 16,991 common shares directly and 30,523 options remaining, which expire on 02/11/2030. The option grant vested in three annual installments from February 12, 2020 to February 12, 2023.

Insider Trade Summary

Exercise and Sale: 61,031 shares ($1.77M approx. pre-tax spread)

Exercise and Sale 3 txns

Insider DANIELS RONALD J

Role Director

Sold 61,031 shs ($3.89M)

Approx. gross sale proceeds $3.89M

Approx. exercise cost $2.11M

Approx. pre-tax spread $1.77M

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	61,031	$0.00	$0.00
Exercise	Common Stock	61,031	$34.65	$2.11M
Sale	Common Stock	61,031	$63.7217	$3.89M

Holdings After Transaction: Stock Option (Right to Buy) — 30,523 contracts (Direct); Common Stock — 16,991 shares (Direct)

Footnotes (2)

1. F1. Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.
2. F2. The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider activity did BridgeBio (BBIO) report?

A director exercised 61,031 stock options at $34.65 and sold 61,031 shares at a $63.7217 weighted average on 11/06/2025.

What price range were BBIO shares sold at in the transaction?

Sales occurred within a range of $63.70–$63.88 per share (weighted average $63.7217).

How many BBIO shares does the director own after the sale?

The director beneficially owned 16,991 common shares directly after the reported transactions.

How many options remain after the exercise and when do they expire?

The director retained 30,523 options, expiring on 02/11/2030.

What was the option exercise price and vesting schedule?

The options were exercised at $34.65 and vested in three annual installments from February 12, 2020 to February 12, 2023.

What is the insider’s relationship to BridgeBio (BBIO)?

The reporting person is a Director of BridgeBio Pharma, Inc.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/07/2025 - 06:03 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DANIELS RONALD J

(Last) (First) (Middle)

C/O BRIDGEBIO PHARMA, INC.

3160 PORTER DR., SUITE 250

(Street)

PALO ALTO CA 94304

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BridgeBio Pharma, Inc. [ BBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/06/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/06/2025		M		61,031	A	$34.65	78,022	D
Common Stock	11/06/2025		S		61,031	D	$63.7217(1)	16,991	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$34.65	11/06/2025		M			61,031	(2)	02/11/2030	Common Stock	61,031	$0	30,523	D

Explanation of Responses:

1. Represents the weighted average sale price of the shares sold from $63.70 to $63.88 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price for all transactions within the range set forth in this footnote.

2. The shares subject to this option vested and became exercisable in three annual installments from February 12, 2020 to February 12, 2023.

Remarks:

Exhibit 24 - Power of Attorney

	/s/ Will Solis, Attorney-in-Fact	11/07/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.